ERBB2 and breast carcinoma: On the other hand, preclinical studies using breast cancer cell line for anti-HER2 therapy have shown no significant difference in 18F-FDG metabolism following treatment with Hsp90 inhibitor 17-AAG [42] and trastuzumab [43].